百亿美元BD大药,国内还有高手

生物制药小编
Aug 28, 2025

PD-1/VEGF这个靶点,注定将在中国创新药的发展历史上,留下无法磨灭的印记。2025年5月20日,中国药企三生制药宣布和辉瑞达成一项合作,三生制药授予辉瑞PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国内地)的独家开发、生产、商业化权利。根据协议,辉瑞将支付12.5亿美元不可退还且不可抵扣的首付款,整个交易的总金额将超过60亿美元。这是国产创新药对外BD的交易中,首次有超过10...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10